Comparison of HPV vaccine delivery models for the two-dose schedule in England
Author(s): ,
Karen Tiley
Affiliations:
PHE
,
Joanne White
Affiliations:
PHE
,
Michael Edelstein
Affiliations:
PHE
Vanessa Saliba
Affiliations:
PHE
PHE ePoster Library. Tiley K. Mar 21, 2018; 205942; 12638
Dr. Karen Tiley
Dr. Karen Tiley
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Rate & Comment (0)
Abstract The human papillomavirus (HPV) immunisation programme was introduced in the UK in 2008 as a school-based three dose schedule offered to 12-13 year old girls (Year 8). From September 2014 the schedule was changed to two doses at least six months apart. Commissioners and providers for each Local Authority (LA) chose whether to deliver two doses in one year (Year 8 in 2014/15) or across two years (Year 8 in 2014/15 and Year 9 in 2015/16). We assessed the impact of delivery model on vaccine coverage in Year 9 girls in 2015/16.LAs were allocated to one of three performance groups based on reported coverage in 2013/14 - the final year of the three-dose programme (Worst performing <80%, Average >=80 and <90%, and Best performing >=90% coverage). Change in LA performance over the two year period was assessed by delivery model.Of 146 LAs offering a school-based programme with a single delivery model across the LA, 94 (64%) offered it within one year and 52 (36%) across two years. Overall similar two-dose coverage was achieved with both models (86.1% vs. 85.2%). The highest HPV coverage in 2015/16 was reported in the ‘best performing areas' in 2013/14 regardless of delivery model. Average performing LAs maintained similar coverage with either model of delivery (85.5% vs 84.5%). LAs with highest completed coverage for the three dose programme (>=90%) achieved highest coverage when scheduling two doses within year (91.3% vs 86.4%), but the opposite was true for LAs with lowest completed coverage during the three dose programme (75.7% vs 80.9%).Local performance and experience in delivering the HPV programme should inform the choice of delivery model. The model should be chosen considering the wider context that includes many other factors that can influence vaccine coverage.
    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings